The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Dante Pieramici, MD, FASRS; Dean Eliott, MD; and Charles C. Wykoff, MD, PhD, FASRS; provide an overview of macular telangiectasia type 2 (MacTel) and discuss the limitations of current treatments, the evidence surrounding a recently approved cell-based gene therapy, and best practices for implementing this new treatment into management plans.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Summarize the limitations of anti-VEGF intravitreal injection therapies in the management of MacTel.
• Evaluate emerging evidence supporting the use of novel therapies in the management of MacTel.
• Integrate current evidence-based interventions for MacTel into clinical practice to optimize disease outcomes.

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Neurotech Pharmaceuticals, Inc.

Dante Pieramici, MD, FASRS
Medical Director, Clinical Research, California Retina Consultants
Director, California Retina Research Foundation
Partner, California Retina Consultants/Retina Consultants of America
Santa Barbara, CA

Disclosures: Advisory: Perceive Bio; Consultant: 4DMT, Adverum, Eyepoint, Genentech/Roche, Neurotech, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Samsung, Unity; Research Funding: 4DMT, Adverum, Eyepoint, Genentech/Roche, Novartis, Ocular, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Unity

Dean Eliott, MD
Stelios Evangelos Gragoudas Professor of Ophthalmology
Director Emeritus, Retina Service
Director, Surgical Retina Fellowship
Harvard Medical School
Massachusetts Eye & Ear
Boston, MA

Disclosures: Consultant, Stockholder: Alcon, Aldeyra Therapeutics, Ingenia Therapeutics, Neurotech, Pykus Therapeutics, RetMap; DSMB Member: Aviceda, Clearside Biomedical, EyeBio, Ocular Therapeutix; Research Grants: Neurotech; Patent Royalties: Aldeyra Therapeutics

Charles C. Wykoff, MD, PhD, FASRS
Director of Research, Retina Consultants of Texas
Chairman of Research & Clinical Trials, Retina Consultants of America
Houston, TX

Disclosures: Consultant/Honoraria: 4DMT, AbbVie, Acuta, ADARx, Adverum, Alcon, Alimera, Alkeus, Allgenesis, AMC Sciences, Annexon, Apellis, Arrowhead, Ascidian, Astellas, Aviceda, Bausch + Lomb, Bayer, BioCryst, Bionic Vision, Boehringer Ingelheim, Chengdu Kanghong, Curacle, Emmecell, Eyebiotech, EyePoint, Genentech, InGel, Janssen, Kiora, Kodiak, Kowa, Nanoscope, Neurotech, NGM, Novartis, Oak Bay Bio, Ocular Therapeutix, OcuTerra, Ollin, ONL, Opthea, Opus, Osanni, Oxular, Palatin, Perceive Bio, Perfuse, Ray, Regeneron, Regenxbio, RetinAI, Roche, Samsung Bioepis, Sandoz, Sanofi, Santen, Skyline, Stealth, Sylentis, TCG Crossover, THEA, Therini, VH401, Visgenx, Zeiss; Research Grants: 4DMT, AbbVie, Adverum, AffaMed, Alexion, Allgenesis, Alimera, Amgen, Annexin, Annexon, Apellis, Ascidian, AsclepiX, Astellas, Aviceda, Avirmax, Bayer, Boehringer Ingelheim, Chengdu Origen, Clearside, Curacle, Eluminex, Eyebiotech, EyePoint, Genentech, IONIS, IRenix, Janssen, Kalaris, Kodiak, Kyoto DDD, Kyowa Kirin, Nanoscope, Neurotech, NGM, Novartis, Ocugen, Ocular Therapeutix, Oculis, OcuTerra, OliX, Ollin, Opthea, Outlook Therapeutics, Oxular, Oxurion, Perceive Bio, Pykus, Regeneron, Regenxbio, Rezolute, Roche, Shanghai Henlius, Stealth, Skyline, VH401; Stock Options (not owner) From Private For-Profit Entities: InGel, Ollin, ONL, Osanni, Panther, TissueGen, Visgenx, Vitranu

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the diagnosis of MacTel, go:

https://www.gotoper.com/rsjuilb25mactel-activity

Release Date

December 22, 2025

Expiration Date

December 22, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.